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HungaryPhytotherapy Research. 2018;32:1039–1046.Cleistochlamys kirkii (Benth) Oliv. (Annonaceae) is a medicinal plant traditionally used in
Mozambique to treat infectious diseases. The aim of this study was to find resistance modifiers
in C. kirkii for Gram‐positive and Gram‐negative model bacterial strains. One of the most impor-
tant resistance mechanisms in bacteria is the efflux pump‐related multidrug resistance. Therefore,
polycarpol (1), three C‐benzylated flavanones (2–4), and acetylmelodorinol (5) were evaluated for
their multidrug resistance‐reverting activity on methicillin‐susceptible and methicillin‐resistant
Staphylococcus aureus and Escherichia coli AG100 and AG100 A strains overexpressing and lacking
the AcrAB–TolC efflux pump system. The combined effects of antibiotics and compounds (2 and
4) were also assessed by using the checkerboard microdilution method in both S. aureus strains.
The relative gene expression of the efflux pump genes was determined by real‐time reverse
transcriptase quantitative polymerase chain reaction. The inhibition of quorum sensing was also
investigated. The combined effect of the antibiotics and compound 2 or 4 on the methicillin‐
sensitive S. aureus resulted in synergism. The most active compounds 2 and 4 increased the
expression of the efflux pump genes. These results suggested that C. kirkii constituents could
be effective adjuvants in the antibiotic treatment of infections.
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The increasing resistance of bacterial isolates is a high concern in the
therapy of infectious diseases. The widespread and inappropriate use
of antibiotics has contributed to the selection of resistant bacteria. Mul-
tidrug‐resistant (MDR) bacteria show resistance against a broad range of
antimicrobials, and one of the most important resistance mechanisms is
thepresenceofmultidrug‐resistant efflux pumps (EPs). Thesemembrane
proteins have physiological functions, and they are involved in thewileyonlinelibrary.com/extrusion of toxic substances into the environment (Aparna,
Dineshkumar, Mohanalakshmi, Velmurugan, & Hopper, 2014; Webber
& Piddock, 2003).
In Staphylococcus aureus, the most studied MDR pump is the chro-
mosomally encoded NorA, which is a member of the major facilitator
superfamily. NorA can transport hydrophilic compounds, quaternary
ammonium compounds, and dyes. The MepA chromosomally encoded
efflux transporter described in S. aureus belongs to the multidrug and
toxic compound extrusion family.MepA can recognize fluoroquinolones,Copyright © 2018 John Wiley & Sons, Ltd.journal/ptr 1039
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Viveiros, Amaral, & Couto, 2013).
The discovery of plant‐derived antimicrobials has drawn particular
attention (Balogh et al., 2014; Hintz, Matthews, & Di, 2015). Numerous
phytochemicals have minimal toxic activity, and they could be used in
order to overcome drug resistance in bacteria by blocking multidrug
EPs (Stavri, Piddock, & Gibbons, 2007). It is important to note that EP
inhibitors (EPIs) from plant sources can inhibit the activity of bacterial
efflux systems; furthermore, they can potentiate the efficacy of antibi-
otics aswell. It has been described that reserpine, isolated from the roots
of Rauwolfia vomitoria, inhibits the Bmr EP of Bacillus subtilis (Klyachko,
Schuldiner, &Neyfakh, 1997). SeveralBerberis species producing berber-
ine were also found to synthesize 5′‐methoxyhydnocarpin, an inhibitor
of theNorAMDRpumpof S. aureus (Stermitz, Lorenz, Tawara, Zenewicz,
& Lewis, 2000). Cucurbitane‐type triterpenoids, isolated from the aerial
parts of the African medicinal plant Momordica balsamina, have shown
activity against the EP systems of Gram‐positive bacteria (Ramalhete,
Da Cruz, et al., 2011a; Ramalhete, Lopes, et al., 2011b; Ramalhete,
Spengler, et al., 2011c).
The bacterial quorum sensing (QS) is a cell‐to‐cell communication
system that is based on chemical signals, namely, autoinducers (AIs). In
Gram‐negative bacteria, the most common AI is the N‐acyl homoserine
lactone (AHL; Varga et al., 2011). EPs and QS signals play an important
role in the development of bacterial virulence. The QS system and the
AIs are able to influence the expression of transporter genes. These
EPs have the ability to transport AI molecules to the external environ-
ment of bacteria, thus facilitating cell‐to‐cell communication (Spengler,
Kincses, Gajdács, & Amaral, 2017).
Cleistochlamys kirkii (Benth) Oliv. (Annonaceae) is an African medic-
inal plant traditionally used in Mozambique for the treatment of wound
infections, tuberculosis, and rheumatism (Verzár & Petri, 1987).
Previously, in a research for antimicrobial compounds from African
medicinal plants (Cabral et al., 2015; Kolaczkowski et al., 2010;
Madureira, Ramalhete, Mulhovo, Duarte, & Ferreira, 2012; Pereira
et al., 2016; Ramalhete et al., 2010), bioassay‐guided fractionation of
the methanol extract of the root barks of C. kirkii led to the isolationof several compounds with different scaffolds. Among them,
C‐benzylated flavanones, namely, dichamanetin and the α,β‐unsatu-
rated lactone (−)‐cleistenolide, have shown relevant antibacterial activ-
ity against Gram‐positive bacteria, including drug‐resistant strains
(Pereira et al., 2016). Moreover, in the combination with β‐lactam anti-
biotics and vancomycin, polycarpol bearing a triterpenic scaffold exhib-
ited a strong synergistic effect against Gram‐positive resistant strains.
In this study, polycarpol (1) and C‐benzylated flavanones 2–4 and a
heptane derivative (5) were further investigated for their ability as both
EP and QS inhibitors of the efflux systems of Gram‐negative and
Gram‐positive bacteria. Furthermore, the ability of compounds 2 and
4 to potentiate the effect of tetracycline and the fluoroquinolone anti-
biotic ciprofloxacin on methicillin‐susceptible and methicillin‐resistant
S. aureus (MRSA) strains was also described.2 | MATERIALS AND METHODS
2.1 | Compounds tested
Triterpene polycarpol (1), C‐benzylated flavanones chamanetin (2),
isochamanetin (3), dichamanetin (4), and the heptane derivative
acetylmelodorinol (5; Figure 1) were isolated from the methanol
extract of the root barks of C. kirkii, as it has previously been described
(Pereira et al., 2016). The purity of all the compounds was higher than
95% based on high‐performance liquid chromatography analysis and
nuclear magnetic resonance spectroscopy. The compounds were dis-
solved in dimethyl sulfoxide (DMSO).2.2 | Reagents and media
Promethazine (PMZ; EGIS), ethidium bromide (EB), verapamil, tetracy-
cline‐hydrochloride (TET), ciprofloxacin‐hydrochloride (CIP), and
Luria–Bertani (LB) broth, and LB agar were purchased from Sigma‐
Aldrich Chemie GmbH (Steinheim, Germany). The modified LB medium
(LB*) was prepared from yeast extract 5 g/L, tryptone 10 g/L, NaCl
10 g/L, K2HPO4 1 g/L, MgSO4 × 7H2O 0.3 g/L, and FeNaEDTAFIGURE 1 Chemical structures of compounds
1–5
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mented with agar 20 g/L (Difco). pH was adjusted to 7.2. Tryptic soy
broth (TSB), tryptic soy agar, and Mueller–Hinton (MH) broth were
purchased from Scharlau Chemie S. A. (Barcelona, Spain).
2.3 | Bacterial strains
Compounds were evaluated against the Gram‐negative wild‐type
Escherichia coli K‐12 AG100 strain [argE3 thi‐1 rpsL xyl mtl
Δ(gal‐uvrB) supE44], expressing the AcrAB–TolC EP at its basal level
and its AcrAB–TolC‐deleted mutant E. coli AG100 A strain. These
strains were kindly provided by Prof. Dr. Hiroshi Nikaido (Department
of Molecular and Cell Biology and Chemistry, University of California,
Berkeley, CA, USA).
The compounds were further evaluated against two Gram‐positive
strains, S. aureus American Type Culture Collection (ATCC) 25923,
used as the methicillin‐susceptible reference strain, and the methicillin
and ofloxacin‐resistant S. aureus 272123 clinical isolate, which was
kindly provided by Prof. Dr. Leonard Amaral (Institute of Hygiene
and Tropical Medicine, Lisbon, Portugal).
For QS tests, the following strains were used: Chromobacterium
violaceum 026 (CV026) as sensor strain and Enterobacter cloaceae
31298 as AHL producer strain (a clinical isolate from a wound). When
C. violaceum reaches a high cell density, it produces a purple pigment,
namely, violacein (Ballantine, Beer, Crutchley, Dodd, & Palmer, 1958).
2.4 | Determination of minimum inhibitory
concentrations by microdilution method
The minimum inhibitory concentrations (MICs) of compounds were
determined according to the Clinical and Laboratory Standard Institute
guidelines (2017) in three independent assays. The solvent DMSO had
no antibacterial effect.
2.5 | Interaction between antibiotics and compounds
The combined effect of compounds and antibiotics on the growth inhi-
bition of S. aureus was evaluated by the checkerboard method. Two-
fold serial dilutions of antibiotics were prepared in MH broth on the
horizontal rows of microtiter plate and then cross‐diluted vertically
by twofold serial dilutions of the compounds (Wolfart et al., 2006).
For this assay, only the compounds with well‐definedMIC values could
be used. Consequently, the combination assays were carried out on
methicillin‐susceptible and MRSA strains. The dilutions of the antibi-
otics (TET or CIP) were made in a horizontal direction in 100 μl, and
the dilutions of compounds were made vertically in the microtiter plate
in 50 μl. After the dilution of an overnight culture, bacterial cells were
resuspended in MH medium containing 1 × 104 cells and distributed
into each well. The plates were incubated for 18 hr at 37 °C. The cell
growth rate was determined after MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐
2,5‐diphenyltetrazolium bromide) staining, as described elsewhere
(Wolfart et al., 2006). The combination index (CI) values at 90% growth
inhibition (ED90) were determined by using CompuSyn software to
plot 4 or 5 data points for each ratio (www.combosyn.com, ComboSyn,
Inc., Paramus, NJ, USA). CI values were calculated by means of the
median‐effect equation, where CI < 1, CI = 1, and CI > 1 representsynergism, an additive effect (or no interaction), and antagonism,
respectively (Chou & Martin, 2005).
2.6 | Real‐time accumulation assay by Roche
LightCycler real‐time thermocycler
The activity of compounds on the real‐time accumulation of EB was
assessed by the automated EB method (Viveiros et al., 2008) using a
LightCycler real‐time thermocycler (LightCycler 1.5, Roche, Indianapo-
lis, IN, USA). Briefly, an aliquot of an overnight culture of the S. aureus
strain inTSB medium was transferred to freshTSB medium, and it was
incubated until it reached an optical density (OD) of 0.6 at 600 nm. In
case of E. coli, the medium used in the assay was LB broth; the prepa-
ration of the inoculum was similar to the one of S. aureus. The cells
were washed with phosphate‐buffered saline (PBS; pH 7.4) and centri-
fuged at 13,000 × g for 3 min, the pellets were resuspended in PBS
(pH 7.4), and the OD was adjusted to 0.6 at 600 nm. The compounds
were added individually at different concentrations at MIC/2, MIC/3,
MIC/4, or MIC/5 (in double concentrated form) to the EB solution in
PBS. The final concentration of EB was based on the MIC and the fluo-
rescent signal produced by this amount of EB. In case of S. aureus
strains, the concentration of EB was 0.5 μg/ml, for E. coli AG100
1 μg/ml, and in case of E. coli AG100 A, it was 0.25 μg/ml. Then,
10 μl of the EB solution containing the compound was transferred into
standard glass capillary tubes of 20 μl maximum volume (Roche), and
10 μl of bacterial suspension (OD of 0.6 at 600 nm) was added to
the capillaries. The capillaries containing the samples were placed into
the carousel (Roche), and the fluorescence was monitored at the FL‐2
channel in every minute on a real‐time basis.
From the real‐time data, the activity of the compound, namely, the
relative final fluorescence index (RFI) of the last time point (minute 30)
of the EB accumulation assay, was calculated according to the follow-
ing formula:
RFI ¼ RFtreated−RFuntreated
RFuntreated
where RFtreated is the relative fluorescence at the last time point of
EB retention curve in the presence of an inhibitor and RFuntreated is the
relative fluorescence at the last time point of the EB retention curve of
the untreated control having the solvent control (DMSO). Verapamil
was applied as positive control on Gram‐positive strains, and PMZ
was used on Gram‐negative strains.
2.7 | Assay for quorum sensing inhibition
LB* was used for these experiments. The sensor strain C. violaceum
026 and the AHL producer strains E. cloaceae 31298 were inoculated
as parallel lines and incubated at room temperature (20 °C) for
24–48 hr. QS inhibition was monitored by the agar diffusion method.
Filter paper discs (7.0 mm in diameter) were impregnated with 10 μl
of stock solutions (10 mM) of the compounds in DMSO. The discs
were placed between the parallel lines of the sensor and the AHL
producer strains on the surface of the nutrient agar. The plates were
incubated at room temperature for another 24–48 hr, and the interac-
tions between the strains and compounds were evaluated for the
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of growth inhibition of the affected strains, in millimeters. PMZ was
applied as positive control (Varga et al., 2011).2.8 | Expression analyses of genes by real‐time
reverse transcriptase quantitative polymerase chain
reaction
S. aureus ATCC 25923 and S. aureus 272123 strains were cultured in
TSB broth and were incubated overnight at 37 °C with shaking. On
the day of RNA isolation, the bacterial suspensions (OD of 0.6 at
600 nm) were transferred to 10‐ml tubes in 3‐ml aliquots, and 5 μM
of compound 2 or 0.5 μM of compound 4 was added to the tubes,
which were incubated at 37 °C. After 4 hr of culturing, the tubes were
centrifuged at 12,000 × g for 2 min. Pellets were suspended in 100 μl
Tris–EDTA buffer containing 1 mg/ml lysozyme by vigorous vortexing,
and they were incubated at 37 °C for 10 min. The total RNA was iso-
lated in an RNase‐free environment using the NucleoSpin RNA kit
(Macherey Nagel, Düren, Germany) according to the manufacturer's
instructions. Purified RNA was stored in RNase‐free water in nucle-
ase‐free collection tubes and was maintained at −20 °C until quantifi-
cation was performed. The concentration of the extracted RNA
templates was assessed by spectrophotometry at 260 nm. Expression
of the EP genes norA and mepA was studied by reverse transcription
of the total RNA. The data obtained for gene targets were normalized
against the S. aureus 16S ribosomal RNA measured in the same sample.
The primers (Couto, Costa, Viveiros, Martins, & Amaral, 2008) used in
the assay were the following:1. Sequence (5′‐3′) of norA (246 bp)TABLE 1a Combination assays on Staphylo
Staphylococcus aureus ATCC 25923
Combination
Tetracycline + chamanetin (2)
Tetracycline + dichamanetin (4)
Ciprofloxacin + chamanetin (2)
Ciprofloxacin + dichamanetin (4)
Note. Starting concentration of tetracycline: 5.2
Collection; CI = combination index.TCGTCTTAGCGTTCGG
TTTA (Fw)
TCCAGTAACCATCGGC
AATA (Rv)2. Sequence (5′‐3′) of mepA (198 bp) TGCTGCTGCTCTGTTC
TTTA (Fw)
GCGAAGTTTCCATAAT
GTGC (Rv)3. Sequence (5′‐3′) of 16S rRNS (492 bp) AGAGTTTGATCMTGGC
TCAG (Fw)
GWATTACCGCG
GCKGCTG (Rv)Real‐time quantification of the RNA templates by real‐time one‐
step reverse transcriptase quantitative polymerase chain reaction was
performed in a CFX96 Touch real‐time PCR detection system (Bio‐Rad,coccus aureus ATCC 25923 stra
Best ratio
1:20
1:1
1.3:12.5
1.3:1
μM; ciprofloxacin: 2.6 μM; and cHercules, CA, USA), and the manufacturer's recommendations of the
SensiFAST™ SYBR No‐ROXOne‐Step Kit (Bioline GmbH, Luckenwalde,
Germany) were strictly adhered to. Briefly, each well of the 96‐well
microtiter plates in a final volume of 20 μl contained 10 μl of the 2×
SensiFAST™ SYBR No‐ROX One‐Step Mix, 0.2 μl reverse transcriptase,
0.4 μl RiboSafe RNase Inhibitor, 5.4 μl diethyl pyrocarbonate‐treated
water, 500 nM of each primer, and approximately 20 ng of the total
RNA inRNAase‐freewater. Thermal cyclingwas initiatedwith a denatur-
ation step of 5 min at 95 °C, followed by 40 cycles, each of 10 s at 95 °C,
30 s at 57 °C, and 20 s at 72 °C.3 | RESULTS
3.1 | In vitro antibacterial activity of compounds
Compounds (1–5) were assessed for their antibacterial activity against
methicillin‐susceptible S. aureus ATCC 25923, and the methicillin‐ and
ofloxacin‐resistant S. aureus 272123 clinical isolate. Wild‐type E. coli
K‐12 AG100 strain, and E. coli AG100 A strain, overexpressing and
lacking the AcrAB–TolC EP system, respectively, were used as Gram‐
negative models. In addition, the antibacterial activity of the
compounds was tested on QS strains C. violaceum and E. cloaceae.
Concerning the antibacterial effect of the compounds, chamanetin
(2) and dichamanetin (4) had a potent antibacterial effect on the
S. aureus strains. MIC value of compound 2 was 12.5 μM on reference
S. aureus; however, the MIC of the methicillin‐ and ofloxacin‐resistant
strain was 25 μM. Compound 4 was the most effective flavanone
because its MIC value on S. aureus ATCC 25923 was 0.8 μM; further-
more, on the methicillin‐resistant strain, it was 1.56 μM.
The compounds had no antibacterial effect on the Gram‐negative
E. coli AG100, AG100 A, C. violaceum, and E. cloaceae strains.3.2 | Combination effects of chamanetin (2) and
dichamanetin (4) with antibiotics
The type of interaction between the antibacterial C‐benzylated flava-
nones 2 and 4 and tetracycline and the fluoroquinolone antibiotic
ciprofloxacin was evaluated on methicillin‐susceptible (ATCC 25923)
and MRSA strains by the checkerboard assay. The results are
presented in Tables 1a and 1b as CI values. CI values <1 indicate a
synergistic interaction between the compound and the antibiotic
(Chou & Martin, 2005). As it can be observed, the combined effect of
TET and compound 2 or 4 on S. aureus ATCC 25923 resulted in syner-
gism. The most effective ratio of antibiotic and compound was 1:20in
CI at ED90 SD (+/−) Interaction
0.63786 0.13419 Synergism
0.42093 0.10354 Synergism
0.81577 0.23974 Slight synergism
0.68615 0.27953 Synergism
ompound 2: 25 μM and compound 4: 2 μM. ATCC = AmericanType Culture
TABLE 1b Combination assays on MRSA 272123 strain
Staphylococcus aureus 272123
Combination Best ratio CI at ED90 SD (+/−) Interaction
Tetracycline + chamanetin (2) 6:25 1.4595 0.29390 Antagonism
Tetracycline + dichamanetin (4) 100:1 0.59402 0.34521 Synergism
Ciprofloxacin + chamanetin (2) 13:8 0.85030 0.21648 Slight synergism
Ciprofloxacin + dichamanetin (4) 32:1 1.35064 0.24946 Moderate antagonism
Note. Starting concentration of tetracycline: 100 μM; ciprofloxacin: 64 μM; and compound 2: 50 μM and compound 4: 3 μM. Ratio: antibiotic and tested
compound (μM). CI < 1, CI = 1, and CI > 1 represent synergism, an additive effect (or no interaction), and antagonism, respectively. CI = combination index;
MRSA = methicillin‐resistant Staphylococcus aureus.
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compounds 2 and 4, being the most active ratio of antibiotic and com-
pound 1.3:12.5 and 1.3:1, respectively (Table 1a).
Against the MRSA strain, compound 2 showed antagonistic effect
withTET and slight synergism with CIP. The interactions of compound
4 withTET and CIP on the MRSA strain were synergism and moderate
antagonism, respectively (Table 1b).3.3 | Efflux pump‐inhibiting activity
The EB accumulation assay provides information about the intracellu-
lar accumulation of the general EP substrate EB. A potential EPI
increases the fluorescence level of EB because of its accumulation
within the bacterial cell. The EP‐inhibiting activity of the compounds
was compared on the basis of the RFI of the real‐time accumulation
curves in Gram‐positive and Gram‐negative strains (Figure 2a). In case
of real‐time EB accumulation by the LightCycler thermocycler, the
amount of EB accumulated by cells is higher if the difference between
RFtreated and RFuntreated is greater; therefore, the degree of inhibition of
the EP system by the compound becomes greater.
As shown in Figure 2a, compounds 2, 3, and 5 had EP‐inhibiting
activity compared with verapamil (RFI: 0.29) on the S. aureus ATCC
25923 strain, and the most active compound was compound 2. How-
ever, compounds 1–5 had no EPI activity on the MRSA strain at the
concentrations applied in the assay.
Concerning the inhibitory activity on Gram‐negatives, triterpene
polycarpol (1) and acetylmelodorinol (5) compared with the PMZ
(RFI: 0.15) could inhibit the AcrAB–TolC system of E. coli AG100. Com-
pound 1 proved to be the most effective EPI (Figure 2a). On the basis
of the real‐time accumulation data, compounds 1–5 had no effect on
the E. coli AG100 A strain lacking the AcrAB–TolC pump.3.4 | Anti‐quorum sensing activity
The QS inhibition activity of compounds was defined measuring the
colorless zone around the disc on C. violaceum as described previously
(Varga et al., 2011). Compounds 1, 2, 4, and 5 were able to inhibit
effectively the QS between CV026 and E. cloaceae compared with
the positive control PMZ (Table 2).3.5 | Relative expression of efflux pump genes
In order to evaluate the effect of compounds on the relative expres-
sion of EP genes in both S. aureus strains, the most effectivecompounds 2 and 4 were selected for gene expression studies. In the
real‐time quantitative RT‐PCR assay, the genes of NorA and MepA
transporters were investigated. As shown in Figure 2bA, compound 2
at 5 μM significantly up‐regulated the expression of norA and mepA
genes after 4 hr of exposure in the MRSA strain. Compound 4 at
0.5 μM also significantly up‐regulated both EP genes after 4 hr of
exposure in the MRSA as presented in Figure 2bB. In the S. aureus
ATCC strain, the expression level of the mepA gene was not influ-
enced; nevertheless, the norA gene was significantly up‐regulated by
compounds 2 (19.84‐fold increase) at 5 μM and 4 (2.39‐fold increase)
at 0.5 μM (data not shown).4 | DISCUSSION
Natural compounds isolated from plants represent a valuable source of
new antibacterial agents. When analyzing the results, the potent anti-
bacterial activity found for dichamanetin (4) and also the significant
activity of chamanetin (2) corroborated our previous studies on this
set of rare C‐benzylated flavanones (Pereira et al., 2016). The strongest
activity of dichamanetin (4), when compared with chamanetin (2),
seems to be due to its higher lipophilic character resulting from the
extra benzyl group at C‐6. In contrast to chamanetin (2), isochamanetin
(3), differing only in the position of the benzyl group, was inactive at
the concentration tested. Thus, besides the importance of lipophilicity,
the presence of a benzyl moiety at C‐8 appears to play a decisive role
in the antibacterial activity of this type of compounds.
In the combination assays, chamanetin (2) and dichamanetin (4)
had synergistic activity with tetracycline and ciprofloxacin on the
S. aureus ATCC 25923 strain. Furthermore, on the MRSA strain,
dichamanetin (4) and chamanetin (2), combined with tetracycline and
ciprofloxacin, respectively, also showed synergism, which indicates
that these compounds could be potential adjuvants in the therapy.
Besides having an antibacterial effect, both compounds (2 and 4)
could inhibit the activity of EPs, they were QS inhibitors, and they sig-
nificantly increased the expression of EP genes norA and mepA after
4 hr of exposure in the MRSA strain. Furthermore, the NorA and MepA
pumps of the MRSA strain could not be inhibited because of the over-
expression of these pumps. The change in gene expression could be
due to the stress response against compounds 2 and 4 because these
compounds as potential noxious agents for S. aureus had to be
extruded from the cytoplasm as soon as possible. This stress response
can be the explanation for the up‐regulation of the EP genes after 4 hr.
The difference between MRSA and ATCC is due to the overexpression
TABLE 2 Inhibitory effects of compounds 1–5 on QS signal
transmission
Compound QS inhibition zone in mm
1 51
2 50
3 —
4 53
5 52
Promethazine 46
Note. Ten microliters of 10 mM stock solution was added into the filter
paper discs (10 μM per disc), and the colorless zone around the disc mea-
sured on Chromobacterium violaceum was measured after incubation for
24–48 hr at room temperature. QS = quorum sensing.
FIGURE 2 Theminimum inhibitory concentration
(MIC) and efflux pump modulating effect
of compounds 1–5. (a) Relative final
fluorescence index (RFI) for the effect of
compounds 1–5 on the AcrAB–TolC‐
expressing Escherichia coli AG100 and
Staphylococcus aureus American Type Culture
Collection (ATCC) 25923 strains. (b) Relative
gene expression levels of norA and mepA
genes in the presence of (A) chamanetin
(2) and (B) dichamanetin (4) in methicillin
resistant Staphylococcus aureus (MRSA)
272123, after 4‐hr exposure. The line
denotes the threshold value, which was set at
a twofold increase in transcripts
1044 KINCSES ET AL.of themepA gene in the resistant strain and it has low expression level in
the ATCC strain. Compounds 2 and 4 increased the expression of mepA
gene in the MRSA, but in the ATCC strain, these compounds did not
influence the expression level of mepA. It has been demonstrated by
other studies that the overexpression of EPs confers a fitness cost
for the organism, for example, a resistant isolate overexpressing
EPs shows reduced production of virulence determinants. Usually the
overexpression of pump genes is often related to global effects on
bacterial physiology influencing virulence (Ledda et al., 2017).
In Gram‐negatives, compounds 1–5 had no antibacterial activity.
Polycarpol (1) was the most effective EPI, inhibiting the AcrAB–TolC
transport system in the E. coli AG100 strain. The AcrAB–TolC system
belongs to the resistance nodulation division transporters, utilizing
the proton motive force to extrude toxic agents out of the bacterial
KINCSES ET AL. 1045cell. Since compound 1 had no EPI effect on the AcrAB–TolC pump‐
deleted E. coli strain, it may have a direct EPI effect on the AcrAB–TolC
transporter system. The effect of polycarpol could be due to its high
lipophilicity (Pereira et al., 2016), which can increase the membrane
permeability of bacteria.
In addition to flavanones 2 and 4, polycarpol (1) and
acetylmelodorinol (5) were also able to inhibit effectively the
bacterial communication, suggesting that they could be applied as
anti‐QS agents.5 | CONCLUSIONS
To summarize our findings, C. kirkii constituents, chamanetin (2) and
dichamanetin (4), inhibited the growth of both S. aureus strains. The
three flavanones tested (2–4) increased the accumulation of the EP
substrate EB on sensitive S. aureus strain, and compounds 1, 2, 4,
and 5 prevented the cell‐to‐cell communication. Polycarpol (1) was
an effective inhibitor of the AcrAB–TolC system of E. coli, which might
be explained by its interference with membrane permeability and mod-
ulation of the function of the pump. Dichamanetin (4) and chamanetin
(2) showed synergistic effect on MRSA and sensitive S. aureus strains
implying that they could restore and increase the efficacy of antibi-
otics, especially in MDR infections. It can be assumed that the advan-
tageous properties of C. kirkii constituents can influence the QS system
and operation of EPs decreasing virulence and antibiotic resistance
(Varga et al., 2011).
According to the results, the most active compounds,
chamanetin (2) and dichamanetin (4), could be possible resistance
modifiers because they possess antibacterial, EPI, and anti‐QS
properties; moreover, these compounds might be used as adjuvants
in the antibiotic therapy because they may be able to reduce the
bacterial virulence. Furthermore, they can potentiate the activity of
antibiotics.
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